Frédéric Marin

Title: Frédéric Marin: Innovator in Mitochondrial Research

Introduction

Frédéric Marin is a notable inventor based in Paris, France. He has made significant contributions to the field of mitochondrial research, particularly in the development of compounds aimed at treating diseases linked to mitochondrial reactive oxygen species (ROS) production. With a total of 5 patents, Marin's work is paving the way for innovative therapeutic solutions.

Latest Patents

Marin's latest patents include groundbreaking inventions such as "Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production." This invention focuses on desmethylanethole trithione (AOX) and its derivatives, specifically targeting diseases that are initiated or evolve due to mitochondrial ROS production. Another significant patent is titled "Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production," which emphasizes the use of specific compounds for the prevention and treatment of such diseases.

Career Highlights

Throughout his career, Frédéric Marin has worked with esteemed organizations such as Op2 Drugs and the Institut National de la Santé et de la Recherche Médicale. His experience in these institutions has allowed him to advance his research and contribute to the scientific community effectively.

Collaborations

Marin has collaborated with notable professionals in his field, including Philippe Diolez and Olivier Petitjean. These partnerships have further enriched his research and innovation efforts.

Conclusion

Frédéric Marin stands out as a prominent inventor in the realm of mitochondrial research, with a focus on developing therapeutic compounds for diseases linked to ROS production. His contributions are vital to advancing medical science and improving treatment options for patients.